Biogen Inc. (BIIB) Earnings Call Transcript & Summary

October 30, 2025

NASDAQ US Health Care Biotechnology earnings 69 min

What were the key takeaways from Biogen Inc.'s October 30, 2025 earnings call?

In Biogen's Q3 2025 earnings call, the company reported a 3% revenue growth year-over-year, driven by strong performance from its launch products, which collectively generated $257 million, marking a 67% increase. Non-GAAP diluted EPS grew by 18%, reflecting disciplined cost management and operational efficiency. Management raised its non-GAAP EPS guidance, now expecting a $0.25 per share improvement due to a stronger business outlook and upcoming business development activities. The company remains optimistic about its pipeline and market positioning, particularly in the Alzheimer's and immunology sectors.

What topics did Biogen Inc. cover?

  • Strong Performance of Launch Products: Biogen's launch products generated $257 million in revenue for the quarter, reflecting a 67% year-over-year growth. CEO Chris Viehbacher noted, "the launch products again in this quarter... more than have offset the MS decline on a year-to-date basis."
  • LEQEMBI Growth and Market Dynamics: LEQEMBI's global sales reached $121 million, with an 82% increase compared to Q3 2024. The product is now the #1 prescribed anti-amyloid treatment, capturing roughly half of all new patients treated with such therapies, according to Alisha Alaimo.
  • Pipeline Progress and Future Readouts: Biogen's pipeline includes 10 Phase III or Phase III-ready programs, with significant upcoming readouts expected in 2026. Priya Singhal highlighted that both TOPAZ studies for litifilimab in SLE are fully enrolled, allowing for earlier data readouts.
  • Cost Management and Financial Discipline: The company reported flat operating expenses year-over-year while achieving revenue growth. CFO Robin Kramer stated, "our OpEx growth was still flat over this year," emphasizing the effectiveness of their cost management strategies.
  • Concerns Over MS Product Erosion: Despite strong performance, Biogen faces challenges with TECFIDERA's generic erosion in Europe, which has accelerated. Kramer noted, "we observed an acceleration of erosion, particularly in Europe as generics continue to launch in new geographies."

What were Biogen Inc.'s October 30, 2025 results?

  • Revenue: $3.1B (vs $3B est, +3% YoY)
  • Launch Products Revenue: $257M (up 67% YoY)
  • LEQEMBI Revenue: $121M (up 82% YoY)
  • Non-GAAP EPS: $1.50 (beat by $0.25)
  • Free Cash Flow: $1.2B (strong cash generation)
  • Operating Expenses: $1.1B (flat YoY)

Biogen's Q3 2025 results indicate strong momentum in its launch products and pipeline, positioning the company for future growth. However, the challenges posed by generic competition in the MS segment and operational capacity in Alzheimer's treatment remain key risks. Investors should monitor the upcoming pipeline readouts and market dynamics closely as potential catalysts for stock performance.

Earnings Call Speaker Segments

Tim Power

executive
#1

Thank you, Cynthia, and good morning to all of you. It's a pleasure to have you join Biogen's earnings call for the third quarter of 2025. As part of this call, we will be sharing forward-looking statements, and those come with risks and uncertainties that could lead to actual results differing materially from what we project. A detailed list of risk factors is available in our SEC filings, and I would encourage everyone to take a look at those. You can find our earnings release along with other materials concerning our results, plus the reconciliations between GAAP and non-GAAP figures we discuss today, in the investors' section of biogen.com. The slides for our webcast have also been posted—actually, let me correct that—the slides we will be using on this call have been posted on our website. Joining me today are Chris Viehbacher, our President and Chief Executive Officer; Dr. Priya Singhal, who leads Development; Alisha Alaimo, our President and Head of North America; and Robin Kramer, our Chief Financial Officer. We'll offer some opening remarks and then proceed to the Q&A session. So that we can address as many questions as possible, we kindly request that each of you ask only one question. At this point, I'll hand the call over to Chris.

Chris Viehbacher

executive
#2

Morning, everyone, and thanks, Tim. Could we bring up the first slide? I believe we've turned in a really solid third quarter. What stands out to me especially is that our growth and launch products posted 67% year-on-year growth during Q3. Those launch products, once again this quarter, and looking at the year-to-date picture too, have more than compensated for the MS decline on a year-to-date basis. Leqembi keeps demonstrating strong, sustained sequential growth in global demand, with worldwide sales reaching $121 million. As you may remember, we said during the second quarter that we'd built up inventory levels in China, which gave us higher Q2 sales, and now there's some offsetting effect in Q3. Still, looking at things on a rolling 12-month basis, we're quite pleased with how Leqembi is progressing. The subcutaneous injection of Leqembi for maintenance has now gained approval in the U.S., it has rolled out, and patients are seeing the benefits. Skyclarys is now on the market in 34 markets globally. We've achieved 30% year-over-year revenue growth. That figure is actually lower than even the patient growth, because we have a number of early access programs running in various countries to ensure patients can benefit from the product while we work out pricing with governments around the world. As for Zurzuvae, revenue growth year-over-year came in at 150%. This product is simply remarkable. One of the most fascinating aspects is that I believe we're actually shifting how postpartum depression is perceived. Every single day, media stories appear about this awful condition affecting mothers. Jennifer Lawrence is the latest person to speak publicly about her experience with postpartum depression. So Zurzuvae isn't merely a product. I think we're genuinely transforming the way people view this, and that matters, but it's also fueling substantial revenue growth for us. Turning to the pipeline, once again, very good, strong progress; our litifilimab phase III studies are now fully enrolled, and both are now anticipated to read out during the second half of 2026. Now, I see this as more than just an acceleration. Lupus is an incredibly competitive space. Numerous studies are underway. And one thing you examine commercially with a new product is whether you can recruit patients into clinical trials. Because that serves as a kind of harbinger for how things will play out commercially. So if we can speed things up, and we can do so in a competitive environment, that tells me physicians are already recognizing something special about litifilimab, and I'm definitely encouraged by that — not only because we'll obtain the data sooner, but as I mentioned, I think it bodes well for the product's commercial success over the longer term. We keep expanding our early-stage pipeline. As we'll see shortly, we have what I consider an extremely robust late-stage pipeline. At this point, it makes sense to shift our attention to something earlier in development; a phase I trial of BIIB142 has gotten underway. That candidate is an IRAK4 degrader aimed at autoimmune disease. Over the next 18 months, our plan is in fact to bring an additional three to four molecules into the early-stage pipeline. Beyond that, we remain busy on the business development front. We disclosed the deal to purchase Alcyone Therapeutics. For our company, this acquisition is highly strategic. For treating a range of diseases, ASOs remain an administration route that is needed; we already have other products in this space, including Nusinersen, BIIB080, and tofersen; so this route of administration stands to become far more convenient for patients. Other companies, clearly, are also pursuing ASOs. So for patients receiving intrathecal injections, we believe this will truly be a breakthrough. And we have just brought in a C5aR1 antagonist by way of our licensing arrangement with Vanqua Bio. Immunology drugs have a nice quality: they often give you the chance to build a portfolio within a single product. Following these immunological pathways can open the door to many different indications; and the beauty there is that after you've shown safety, you can move into other indications quite efficiently. Once again, we expect to announce at least one more research-stage deal, possibly two, before the year is out; so let's please go to the next slide; now, this slide is one I love. When I look at it and see the lines stretching the whole way across the page, I think — for a company of our size, 10 phase III or phase III-ready programs, and that includes five phase III mAbs. Our conviction in this pipeline is strong. In phase II we've seen plenty of good data, and we're now nearing a point where many of those readouts will arrive; now, something you probably don't consider is that these aren't merely 10 phase III programs. They are also 10 launches. Take just Felzartamab as an example — that one has four indications. Two of them, AMR and MVI, are transplant. Two of them sit in nephrology; and then, naturally, lupus is coming along with three indications in lupus. And naturally, we remain in rare disease with Zorevunersen; we have a next generation of Spinraza with Salanursen, and we're quite excited about what's coming along with BIIB080 and tau. But every one of those now requires us to start standing up commercial teams, building insights, thinking through pricing, thinking through value propositions. So there's a great deal of activity inside the company. Another thing I like to examine when trying to predict whether things will succeed is this: can we draw strong talent? The reason is that when individuals join a company, they're wagering their professional futures on it—particularly when it involves a brand-new offering. And honestly, I've been incredibly impressed by the caliber of talent we've been attracting to Biogen. To me, that signals that folks are prepared to stake their careers on these thrilling new offerings. Over the course of my career, I've witnessed repeatedly that this tends to convert into commercial triumph. Market research matters, but I believe several of these other signals matter even more. So let's advance to the following slide; what have we been attempting to accomplish across the past three years? The first thing is clearly, let's expand our new product launches; and once more, 67% revenue growth indicates this is an extremely robust performance. We have Leqembi, Skyclarys, Zurzuvae, and even Qalsody. And looking back over the last trailing 12 months, that amounts to nearly $1.2 billion in revenue; and clearly, all of these products possess lengthy runways when it comes to market exclusivity; and in every one of these cases, they are not merely first in class, but the first-ever treatments in these areas. So we're genuinely engaged in a tremendous amount of market creation.

Chris Viehbacher

executive
#3

If you've spent much time in commercial roles, you're aware that building a market from scratch is far harder than entering an already-established market and capturing share from others. I believe that really highlights how commercially capable our teams are at Biogen. Now let's turn to how profitable our legacy business is. Sure, I'd say we exceeded top-line expectations this quarter thanks to MS, but none of that happened by chance. I'd argue we're outperforming virtually every comparable case when it comes to products whose market exclusivity periods have ended. I believe that reflects the strength of our customer care. To me, that speaks to the dedication MS patients feel toward Biogen's offerings — we continue to serve a larger MS population than any other organization. One thing worth keeping in mind: this isn't just about inherited business. Vumerity is an impressive product that's been growing quite strongly throughout this year. It brought in close to $500 million across the first nine months of this year. Its market exclusivity runs well beyond the end of the decade; we take pride in the fact that our U.S. team in particular is directing additional investment into this area, and those efforts are delivering results; within the oral segment — a hugely significant piece of the MS market — it genuinely stands as the only product still under patent protection. We've kept a close eye on running the business efficiently. That $1 billion in gross savings is going to be delivered. From the very start, we were clear that a portion of it would go back into the launch of our new products, and into research and development as well. Revenue has been climbing, yet our OpEx has remained flat throughout this year. Even with all those fresh investments, we've brought more products into late-stage development, and we're handling all the hiring needed to get commercially ready for the launches that have now reached phase III. Taking a look at what we've got coming down the line, development spending is down roughly 25%, while research has been trimmed by 40%. Even so, I'd make the case that what's in the works now beats what we had previously. Much of that comes down to Priya's efforts — she's been rigorous about selecting which products move into development and making sure we have real conviction behind each one. When I review where things stand, what I see is a late-stage pipeline that's both compelling and backed by strong confidence. The rationale behind pursuing these early-stage transactions is that we believe an early-stage pipeline now needs to be established, and Vanqua Bio represents merely one illustration of that effort; our cash flow generation remains robust, and we keep evaluating where opportunities exist throughout the full spectrum for expanding our business. Our approach to deploying that cash flow is, I believe, highly disciplined. Any initiative receiving funding from us must contribute to growth in one manner or another. Having said that, perhaps we can gain further detail on our pipeline, so I will turn it over to Priya.

Priya Singhal

executive
#4

Thank you, Chris. Across the development pipeline, we've achieved meaningful progress during this year, and our position allows us to keep delivering numerous anticipated milestones throughout the coming 18 months. As Chris pointed out, our attention stays fixed on carrying out our strategic objectives, and I want to call out a handful of accomplishments from this quarter. Crucially, as Chris referenced, even with tough competition for trial enrollment in this area, we've completed full enrollment in both TOPAZ studies evaluating litifilimab for SLE; because of that, we can move both anticipated readouts from these trials earlier, into next year, 2026. Moving on, we keep pushing forward two promising new opportunities. The first involves nusinersen, for which the pivotal trial design covering pre-symptomatic infants, along with the wider clinical development plan, has now been aligned with the FDA. We're additionally in discussions with regulators outside the U.S. and anticipate launching the registration study in early 2026. We're likewise continuing to move Felzartamab ahead in late MVI, where a potential registration trial should begin within the next few months. Today, we shared an update regarding high-dose Spinraza, for which the FDA gave us a way forward; we refiled quickly, and a PDUFA date now falls in April 2026. Over these past several years, we've reshaped our pipeline at both late and early stages. Following the science, we've obtained proof of concept to move high-conviction scientific assets into stages that could be registrational. While we push the early-stage assets forward, we keep following the science by examining the most critical scientific hypotheses. We now anticipate several readouts from our pre-POC pipeline arriving next year. Our attention also goes to expanding the pre-POC pipeline, through internal research assets we bring to IND stage, such as BIIB142, our IRAK4 degrader, and through staying deeply involved in pursuing external innovation, which includes last week's announcement, as Chris noted, of a collaboration with Vanqua Bio on a preclinical C5aR1 antagonist. Shifting to our late-stage pipeline, the range of opportunities to further advance our assets scientifically excites me, including our capacity to educate on the profile of our innovative medicines using our data. For instance, this week at ACR, we shared important differentiated data from our positive phase III Dapirolizumab trial, demonstrating a consistent clinically meaningful benefit across outcomes relevant for SLE patients and providers, including flare reduction, fatigue, morning stiffness, musculoskeletal pain, LLDAS, and remission. Reinforcing what we said at our September lupus seminar regarding the potential significance of Dapirolizumab for SLE patients, including women of childbearing age, we presented data showing limited placental transfer in a preclinical setting. Now, I'd like to take a few minutes to discuss the ongoing Leqembi development aimed at providing optionality for Alzheimer's disease patients. As shown on the left side of this slide, we've already succeeded this year in delivering meaningful differentiated treatment options for Leqembi. At present, it stands alone as an anti-amyloid treatment offering a maintenance approach, including one that can be given subcutaneously at home; meanwhile, our rolling submission to the FDA for subcutaneous initiation of Leqembi keeps moving forward. Both the maintenance choice and the ability to deliver the drug subcutaneously may also matter for Leqembi among pre-symptomatic APOE individuals. As shown here, the AHEAD 3 to 45 trial is a significant study designed to thoroughly assess Leqembi across two distinct phases of pre-symptomatic AD, using suitable scientific questions alongside pertinent primary endpoints. On top of that, momentum keeps building around blood-based biomarkers — their creation, clearance, and adoption. We regard this as a crucial facilitator that could streamline diagnostic routes; our enthusiasm persists, and we think Leqembi's prospects within the pre-symptomatic AD group may represent a major opportunity for Biogen; to wrap up, it heartens me that Leqembi AHEAD 3 to 45 is merely one among a number of key registrational results expected in the coming years. On this slide, you can observe that our pipeline, grounded in strong scientific belief, will be essential amid the growing pace of our registrational data output. It starts with a pair of litifilimab phase III results in SLE next year, and from 2027 onward, we will witness numerous registrational readouts spanning multiple assets in varied and significant therapeutic fields; having said that, I'd like to pass the call to Alisha now for a commercial business update.

Alisha Alaimo

executive
#5

Thanks, Priya, and good morning to all of you. During today's call, I'll walk through the commercial results from Q3, starting with the multiple sclerosis portfolio. Revenue from our MS business remains substantial, and that money fuels investment in our growth products, lets us move the pipeline forward, and helps us realize what we envision for the new Biogen. Performance in the U.S. was strong, largely the result of strategic moves made to support Vumerity's expansion along with a few one-time events. Looking at how competition is behaving around the world, the effect of Tecfidera generics keeps growing in Europe, and where Tysabri is concerned, we feel well positioned for the biosimilar entrant coming in the U.S. Turning to Leqembi: it delivered another robust quarter, as global sales climbed 82% compared with Q3 2024, underscoring the expanding difference it makes for Alzheimer's patients around the world. Here in the U.S., our people collaborate tightly with Eisai, performing well and connecting effectively with customers, something we believe contributed to a further 14% quarter-over-quarter increase in our prescriber base. Across this quarter, the rise in both new prescribers and new patients remained steady, and Leqembi keeps the largest share as the anti-amyloid therapy prescribed most often. Looking back at 2025 as a whole, our estimate is that Leqembi accounted for about 50% of every patient newly starting an anti-amyloid therapy. And now, thanks to the introduction of the IQLIK subcutaneous auto injector for maintenance, Leqembi stands alone as the first and only anti-amyloid option delivering an at-home injection, which hands physicians, patients, and care partners additional choices for keeping disease progression slowed after the initial 18-month treatment period wraps up. What we've heard so far from customers and payers has been encouraging, and as we move into next year, our focus stays on locking in Part D coverage and helping patients get access to Leqembi. During the prior quarter, we pointed out that we saw, for the first time, early indications that the anti-amyloid market expanded with two competitors in it. This quarter's data has us feeling positive, since it indicates the market kept expanding at a rate of about 15%. We also noted that testing via blood-based biomarkers was progressing rapidly, and on that front, our physicians have highlighted a substantial effect. According to their reports, blood tests assist in shifting from a probable diagnosis to a definitive one at a faster pace, which lets HCPs, patients, and their families devote more attention to discussing treatment. For this year, we expect as many as 350,000 Alzheimer's blood tests, along with over 60,000 PET scans recorded so far — a 75% rise from the same point last year. According to what our data is showing, there are early signals that positive PET CSF tests are on the rise, and in our view this could stem from greater adoption of Alzheimer's blood diagnostics as a triage mechanism. We've mentioned before that we're working to inform HCPs regarding the quality of blood-based biomarkers, and that includes how BBMs perform when they satisfy what the Alzheimer's Association's updated practice guidelines call for in terms of amyloid triage and confirmation. Looking ahead to 2026, our expectation is that Leqembi's momentum will keep being propelled by the focused strategies we've put in place, and we think those are already making a favorable difference when it comes to intent to prescribe, how efficacy and safety are perceived, and how well healthcare providers grasp the role that anti-amyloid therapies play. Now shifting to Skyclarys, where patient numbers keep climbing in every territory thanks to the launch, the U.S. and international markets included. Skyclarys has reached 34 countries at this point, fueling a solid 30% increase versus the equivalent period a year ago. Stateside, quarter-over-quarter patient gains have continued as anticipated, though Q3 revenue took a hit from channel mix amid the Medicare adjustments tied to the IRA. Our U.S. approach, as previously discussed, centers on connecting with the remaining Friedreich's ataxia patients, together with their neurologists and PCPs, who according to our data are mostly located in community settings. We're concentrating our work on fulfilling that objective, since close to two-thirds of Q3's new patients came via prescriptions from first-time writers, while PCPs authored approximately a quarter of new scripts. Internationally, our attention stays on further geographic expansion, and we have several commercial launches lined up during the first half of 2026. Finally, onto Zurzuvae, still exceeding what we had anticipated. Our enlarged field team, as mentioned earlier in the year, has made a substantial difference, generating $55 million within the U.S., representing 19% revenue growth versus the prior quarter. We're likewise buoyed by the widening base of writers, up 19% quarter over quarter. During quarter three, 80% of Zurzuvae prescriptions came as first-line, which shows healthcare providers' confidence in the worth of a therapy delivering swift relief for mothers dealing with postpartum depression. Looking across our portfolio, I take pride in our teams for carrying out our strategic priorities with discipline. Their dedication helps us serve patient communities, establish new markets, and generate sustainable growth. I'll hand things over now to Robin for an update on our financial results.

Robin Kramer

executive
#6

Thanks, Alisha. I'd like to walk through a few important points regarding the solid financial results we posted for the third quarter. Except where I say otherwise, every comparison I'm about to make is against the third quarter of 2024. Revenue grew 3% in the quarter, powered by ongoing strong commercial execution. Our four launch products brought in $257 million of revenue during the quarter, which works out to 67% growth. We kept seeing resilient performance from our U.S. MS business, helped favorably by gross-to-net adjustments, shipment timing, and robust demand growth for Vumerity. Partly offsetting that was continued generic erosion of Tecfidera in Europe. What really matters here is that the money we brought in so far this year from our newly launched products has completely offset the drop in year-to-date revenue from our MS products. Thanks to that commercial execution and the careful way we've managed operating expenses, our non-GAAP diluted EPS grew 18% for the quarter. On top of that, we brought in $1.2 billion of free cash flow in the quarter. Turning to guidance: the strong business trends we continued to see in Q3 give me confidence, and that comes through in our raised revenue outlook. As you'll notice, we've revised our non-GAAP EPS outlook to capture that stronger business picture while accounting for anticipated business development activities that should close in the fourth quarter. I'll walk you through the specifics of that in a moment. I'd like to walk through a few important pieces of how we did on revenue in Q3. Starting with MS, our franchise: on top of the solid commercial work Alisha described, Vumerity picked up about $22 million thanks to favorable inventory movements, and for U.S. MS as a whole, gross-to-net adjustments gave us a favorable boost of $38 million during the quarter. Beyond the U.S., generic pressure on Tecfidera that we had anticipated was the main driver of sales. We continue to protect our intellectual property. Even so, erosion moved faster, particularly in Europe, since generics kept entering additional markets, Germany among them. Combined with the channel dynamics, that led to a $28 million sequential decline in Tecfidera revenue in Europe compared with the previous quarter. Looking at the brighter side, in Europe the Tysabri IV biosimilar's effect both year over year and quarter over quarter was largely canceled out by rising uptake of our subcutaneous version, for which no biosimilar exists, and that version now represents over half of all natalizumab patients—branded and biosimilar combined—across Europe. Regarding Spinraza, global demand continues to look solid to us, and as we had anticipated, XUS Spinraza took a hit from the unwinding of inventory stockpiles built up during the first quarter. Our projection remains that worldwide Spinraza revenue for the entire year will be about the same in 2025 as it was in 2024. Moving on to the products we've launched, starting with Leqembi, we continue to observe reliable growth in end-market demand worldwide on a sequential basis, with roughly $121 million in third quarter end market sales recorded by Eisai. On the China front, you may recall that during the previous quarter we accumulated $35 million worth of inventory, which equated to about half a year's worth of regional demand. During Q3, approximately 50% of that stock got drawn down. Consequently, just as we had expected, sales recorded in China during Q3 were close to zero, since the channel's existing inventory was sufficient to satisfy demand; we continue to expect that demand in China for Q4 will be covered by the inventory we still hold, meaning only minimal revenue will be booked there in the fourth quarter. Skyclarys continued its global expansion, delivering a 30% revenue increase compared with the year-earlier period; in the U.S., although we saw sequential growth in patients, that was counterbalanced by an approximately $6 million adjustment related to channel mix stemming from the Medicare-driven IRA redesign. We anticipate Skyclarys will keep expanding, and we're pursuing reimbursement in selected European markets and in Latin America. As Alisha mentioned, we're happy to see Zurzuvae maintain robust growth on the strength of higher demand; now, some remarks about the remaining P&L lines. Before turning to the quarterly dynamics, I want to call out the variance you see here between GAAP and non-GAAP cost of sales. GAAP cost of sales came to $674 million, a 6% increase year-over-year, reflecting an approximately $100 million pre-tax charge accrued in Q3 tied to a judgment on Genentech's claim for past royalties and interest concerning Tysabri. Excluding that effect, the figure would have been roughly $570 million, an 11% decline year-over-year. Looking more widely, our cost of sales benefited because of a better product mix, which came about since we had less contract manufacturing revenue during Q3 2025—and that revenue brings a thinner margin with it. That same trend ought to hold through the remaining months of the year, since the campaign schedule for contract manufacturing is what we already described previously. When we talk about non-GAAP core operating expense—R&D along with SG&A—it's unchanged compared with a year ago. What our results show is that we remain disciplined about cost management, even as we keep meeting our R&D prioritization goals and our fit-for-growth initiatives, and at the same time we ensure continued backing for investments in our launch products and in our longer-term growth potential. Let me turn now to a brief balance sheet update. Thanks to how the business performed and our continued discipline on costs, we generated roughly $1.2 billion in free cash flow this quarter. When the quarter ended, we held $4 billion in cash and marketable securities, plus $2.3 billion in net debt. This financial strength gives us room to put money back into strategic growth efforts — for example, moving our pipeline forward, backing product launches, and looking into growth opportunities as we work to deliver the new Biogen. Turning to guidance: we have adjusted our non-GAAP EPS guidance to reflect both a stronger underlying business outlook and investment for growth tied to business development transactions we expect to close in the fourth quarter. As you're aware, the SEC mandates including acquired IPR&D charges linked to business development transactions in both GAAP and non-GAAP financial results; and since those one-time charges, our business outlook has kept strengthening during the quarter, producing a $0.25 per share improvement. Included in our revised outlook for the entire year is an impact of about $1.25 per share tied to business development deals anticipated to be finalized in Q4, among them the licensing arrangement with Vanqua Bio along with the purchase of Alcyone Therapeutics. Here are several important points that form the basis of our financial projections. At constant currency, we anticipate revenue will come in somewhere between flat and a 1% increase versus the prior year, which is better than what we indicated in our July update. That stems from solid commercial execution, among other things the steady results posted by the US MS segment so far this year. Beyond that, we foresee mounting competitive headwinds bearing down harder on the XUS MS segment, especially when it comes to Tecfidera across Europe, and there the quarter-over-quarter effect during Q4 should be about twice the level of decline witnessed in the period just reported. Furthermore, as we noted heading into July, we're putting money behind promising chances to broaden the pipeline, among them a fresh effort involving Felzartamab and MVI plus the phase III trial of Felzartamab that Priya covered earlier on this call. As was brought up previously on this call, we're likewise starting to fund pre-launch work tied to our late-stage high-conviction pipeline as well as key efforts like direct-to-consumer advertising behind our launch products; in our view, these outlays leave us well placed to generate growth down the road while still bringing forward novel options for patients. Turning to Q4, we anticipate that operating expenses will land at around $1.1 billion. That mirrors the usual seasonal pattern in our fourth-quarter outlays, the continued spending meant to fuel growth, and our emphasis on keeping costs lean. It likewise mirrors how far our pipeline has come, given the chance to put resources into 10 programs that either sit in phase III or are slated to enter phase III over the next several months. Our momentum in building the new Biogen gives us confidence, and we see real value in making these commitments as we pursue sustainable growth and lasting shareholder value. Crucially, we think we're still on course to realize the $1 billion in growth savings together with $800 million in net savings envisioned under the fit-for-growth initiative before 2025 ends, and as I noted earlier, we project contract manufacturing revenue for Q4 of this year at $10 million to $20 million, reflecting the planned sequencing of contract manufacturing batches relative to manufacturing of Biogen innovator products. Kindly take a moment to go over this slide along with our press release for additional significant guidance assumptions; with that, I'll hand things back to Tim so we can begin taking questions.

Tim Power

executive
#7

Thanks, Robin. Cynthia, could we go to our first question, please?

Umer Raffat

analyst
#8

Hello, everyone, and thanks for taking my question. If I could, I'd like to take a brief moment to discuss a tau trial. What I'd like to know is this: if a trend does emerge, what effect do you expect that to have on the Leqembi franchise? And what matters even more, in what way does that shift how you're thinking about the portfolio offering you have in this area? In a situation like that, would having a Lilly collaboration or an asset in-house be necessary? Thanks so much.

Chris Viehbacher

executive
#9

Regarding that study, I suppose we should wait to see the findings and determine where the impact will land. We've examined it. If the outcome is favorable, our belief is that it would likely see greater adoption in primary care at an earlier point; we'll need to check again what the findings show, yet it doesn't appear this would truly influence plaque levels. That said, I do believe that as an organization, we're keen on possessing a complete portfolio of products for tackling Alzheimer's. We've got the BIIB080 program and are clearly developing brain shuttle technology. So my sense is we'd likely assess that once the data become available. There's definitely no shortage of GLP-1s around.

Priya Singhal

executive
#10

One more point I'd like to make: the key thing, as I see it, is that their hypothesis centers on neuroinflammation having a significant part to play, and like Chris said, my sense is that it isn't truly aimed at the pathology. What matters is that patients in the EVOKE trials were on stable doses of Alzheimer's treatment, the anti-amyloid antibodies among them, so seeing those data will be of interest to us, and we also think it will raise awareness of the disease along with the necessity of treating it early.

Tim Power

executive
#11

Thanks, Priya. Let's go to our next question, please.

Evan Seigerman

analyst
#12

Hey, everyone. I really appreciate you letting me ask something. Stepping back a bit, what you've achieved in immunology genuinely stands out to me. Could you explain how this sharper emphasis might fuel growth and broaden the pipeline through the rest of this decade? Also, what's possible alongside Biogen to speed up certain of those programs?

Chris Viehbacher

executive
#13

I'll take that first part. Upon joining Biogen, my position was that immunology has always been part of who we are, since many conditions, MS included, get treated by attempting to influence the immune system. As I've mentioned, none of our MS therapies even get past the blood-brain barrier. So my view is that immunology has always been our business. Over the past 10 years, immunology has truly thrived as a field. In my view, Dupixent stood out among the earliest medicines to show disease-modifying potential when those pathways are targeted. Naturally, those can produce a broad spectrum of activity; that's something we grasp; near term, our emphasis leans toward rare immunology plus immunology that intersects with spaces where we already possess some background. Take lupus, for instance. Lupus is a highly complicated condition involving numerous symptoms and issues that patients deal with, and the expertise Biogen has gained in MS should translate directly to lupus, and I believe we can grow that market in ways that established companies selling their products have not managed. Over time, I believe we can genuinely assemble a portfolio of products with wide-reaching effects across immunology. The opportunity here is substantial. Much remains that we don't yet grasp, and looking ahead roughly five years, the focus sits more within rare immunology, yet on a 10-year horizon, I believe we can move into broader indications, and Vanqua is merely a single instance of acquiring an asset potentially suitable for multiple indications. You'll likely see additional moves like that from us. Once more, these are spaces requiring genuine depth of scientific knowledge about how such pathways function. Numerous elements intersect. One example we observe even in disease involves NRF2, microglia, and similar factors that span multiple diseases; that intersection, I believe, is something we can contribute to the immunology side as we pursue various indications. Consider Felzartamab as well — while we're in four kidney indications, we're examining another three that have no connection to kidney. Again, since we grasp things such as neurofilament and others, we believe we may hold insights enabling us to create medicines that rival companies cannot. So for us, this is a central area. We are in no way walking away from neuroscience. Our commitment in Alzheimer's and ALS remains really substantial. We've also got a major effort underway in Parkinson's. That said, immunology strikes me as an excellent area for Biogen. Thanks, Priya. Bonnie, anything you'd like to add?

Evan Seigerman

analyst
#14

Let's move on to the following one. Thank you, Chris.

Salveen Richter

analyst
#15

Hello, good morning, and I appreciate you answering my question. You brought up an emphasis on growing the early-stage pipeline through BD, and that's in part motivated by the late-stage pipeline, where roughly 10 phase III trials are currently underway. Might you elaborate on the assurance in that later-stage work that gives you the ability to concentrate on the earlier set of programs?

Chris Viehbacher

executive
#16

There are, I'd say, two components to what you're asking. The assurance regarding the late-stage pipeline. For sure, when it comes to Felzartamab, we believe we've observed fairly compelling phase II data. Of course, risk always exists when you move into phase III, but what we've seen — if you consider just AMR, for instance — was an 80% resolution of AMR among patients; in IgAN, we found that even two years following a patient's final treatment, a benefit was still apparent. That leads us to think we possess a disease-modifying effect in IgAN. Those are all points regarding Felzartamab; regarding BIIB080, clearly, the work we're doing is pioneering. Reducing tau to the levels we anticipate being capable of has essentially never been done by anyone; the outcome of that trial remains to be seen. When I consider lupus, once more, our phase II results were very strong. Especially in CLE, where no drug has been approved as of yet, our belief is quite strong. Dupixent has already demonstrated itself in one phase III. Therefore, running a second phase III would appear to carry a reasonably high likelihood of success. And I think, once more, even regarding SLE and litifilimab, it's a space the company has spent quite a long time working on. So research and development never comes with a guarantee, but I believe we've transformed the pipeline from many moonshots, so to speak, into something where we've actually achieved a thoughtful progression and de-risking of our pipeline; and when I consider the peak sales potential of that late-stage pipeline relative to our existing

Tim Power

executive
#17

Okay, thank you, Cynthia. My apologies — the call dropped on us. Chris, could you please answer that most recent question once more, if that's all right with you?

Chris Viehbacher

executive
#18

Right, I'm not certain exactly where we left things. It's curious — despite the hundreds of billions of dollars pouring into data centers and AI, we've still got telephones, op calls. Yeah. So, regarding that, once more, we hold strong conviction about both late-stage and early-stage; at present we're developing substantial commercial capability as we get ready to launch that late-stage asset, accumulating a great deal of expertise and knowledge in immunology. And at this point it makes sense to keep going and extend that into the early stage. Many companies become so fixated on launches and the late-stage pipeline that research occasionally gets overlooked; yet right now is truly the moment to put money into the next generation of products; and in my view there has never been a better moment to work in immunology. And I believe Biogen is perfectly positioned for it.

Tim Power

executive
#19

Thanks, Chris. Let's go to the next question, please, Cynthia.

Brian Abrahams

analyst
#20

Hello, good morning, and thank you for taking my question. This might be one for Alisha. Could you share some insight into the initial experience regarding Leqembi SubQ maintenance uptake and access, specifically around non-formulary exceptions, what the possible timelines could be for securing formulary placement, for both maintenance and induction, and perhaps whether we ought to consider net price here, ultimately arriving at parity between the IV and SubQ versions? Thanks.

Alisha Alaimo

executive
#21

Okay. I appreciate the questions. To this point, I'd say the response has been quite favorable, not just from payers, but also from HCPs and patients; beyond that, we expect that SubQ maintenance will allow patients to remain on therapy for a longer period. So we view it as a significant upside. Providers and patients will need some time to get used to this new outpatient treatment modality, even when used as maintenance; nonetheless, we regard this as an excellent bridge as we progress toward the possibility of SubQ initiation. So a gradual uptake is what we anticipate, though in time it will turn into a meaningful driver for long-term therapy and for the outcomes of our treatment. Right now and through next year, the teams are doing a couple of things: first, they're educating sites about what you mentioned, that non-formulary exemption process. That said, payers have indicated this shouldn't create difficulties for HCPs who want to move their patients off IV, and we already know of the first patient who successfully worked through this process alongside their physicians, and we're also aware that several patients are already receiving SubQ. In addition, we have a companion that has been rolled out to the entire market, which has also assisted patients with performing the auto injection, ensuring their shipments arrive, and ensuring physicians feel at ease. Furthermore, when it comes to the non-formulary exemption process, looking at analogs on the market beyond Alzheimer's disease, approval rates tend to be pretty high; so once again, we don't expect that to be problematic, and then second is working through this Medicare Part D formulary and the cycle with the aim of securing access for patients throughout the country; so that process for Medicare is underway right now. And our belief is that we'll have full access by 2027; until then, however, they do go through the non-formulary exemption process. Still, ultimately, what we're hearing is that subQ Leqembi is truly just a wonderful option for patients and physicians. As a matter of fact, just the other day, I spoke with a physician who had administered his 10,000th infusion of Leqembi; and he told me some of his patients are extremely excited; they're able to go on vacation. They can bring this along with them; and it's now giving them the freedom to travel even more than they currently do. So far, so good as we head into 2026. We also think that getting started will actually serve as a strong boost for us too.

Tim Power

executive
#22

Thanks, Alisha. Let's go to the next question, please.

Paul Matteis

analyst
#23

Hi there, and thanks for letting me ask. Interest keeps building around the prevention trials that Lilly, you folks, and Eisai are conducting. I suppose my question is a wider one. If those trials read out positively, how are we supposed to view the commercial side? Clearly, a favorable result could substantially shift how people talk about what these beta drugs can do. What our team finds difficult, though, is that treating the diagnosed population remains genuinely hard. Capacity constraints are everywhere, MRIs included. The supply chain has been extremely, extremely intricate. So to me it seems that diagnosing patients in the first place, plus getting providers mobilized to treat people with no symptoms, could stir up even bigger capacity problems and hurdles across that entire chain of using and monitoring these medicines. So how would you respond to that? What can you all do to get ready for a good result here and truly deliver a meaningful ROI? Thanks.

Chris Viehbacher

executive
#24

I'll handle that one.

Alisha Alaimo

executive
#25

Appreciate that question. I'll take it; we've spent a lot of time on this, clearly, with the main focus being the possibility of a trial succeeding, sorting out if that ends up being Lilly's study or Eisai Biogen's study. One thing we're examining, particularly around the PCP space, is how they boost the quality of referrals they send to physicians. As I mentioned, blood-based biomarkers are expanding quickly. Also, Roche recently got approval for a BBM named Elecsys. That one is really just a rule-out BBM. It's cleared for a primary care setting, which essentially assists them with this kind of asymptomatic or very early-stage Alzheimer's disease. So we think, via some of the field's education efforts — and by the way, we aren't alone in this — there are multiple organizations backing these efforts to ensure physicians grasp that many of these BBMs satisfy the criteria for confirmation; and what we're observing is that in a pilot we're currently running, which we'll report after the next quarter, is whether we can genuinely enhance the prescribing or the diagnosing and then also the referral and that referral's quality. I will say, though, that already in PET/CSF we're seeing the positivity rates for those tests climb dramatically too. When this journey started, we sat at 50/50, positive versus negative; and now we're north and upwards of that figure in positivity. We think that comes from better triaging with the blood-based biomarkers. That's one piece of it. The second piece is, of course, some of these patients then won't fall into Medicare based on their age. It's how we also engage and coordinate with the commercial plans, since they are the ones that would have to cover the product at that point. Obviously, some of those discussions have already taken place because we do have some younger population patients who want to go on product. I do think we're working through that. By the time these trials read out, I do think capacity will also be much better.

Chris Viehbacher

executive
#26

Yes. And I think we can add something to what Alisha just mentioned: once the subcutaneous version is approved — which we expect for both starting treatment and ongoing maintenance — if blood-based diagnostics begin taking the place of the PET scan and the lumbar puncture, you're cutting the burden on neurology by a huge amount. And as we've discussed in earlier calls, much of our effort has gone toward simplifying the care pathway for physicians, with the goal of boosting throughput. And as Alisha correctly noted, right now roughly 50% of patients who manage to secure a visit with their neurologist aren't actually eligible. And once more, as we raise that yield from the referrals, as Alisha mentioned, that will in turn substantially expand the capacity; we should note that there remain a fair number of neurologists who haven't yet started therapy on Alzheimer's. I believe we'll still — as this progresses — I believe we'll see that the capacity will adapt.

Tim Power

executive
#27

Thanks, Chris. Let's go to the next question, please.

Marc Goodman

analyst
#28

Yes. Hello. I'd like to ask about Skyclarys. Could you provide a bit more detail on what's going on internally? You referenced a $6 million hit to U.S. sales, and you touched briefly on reimbursement challenges in OUS markets. How are volumes trending, perhaps domestically and then abroad? Is the patient base expanding? Is persistence holding up well? Are patients dropping off? Just help us understand the Skyclarys situation a bit further. Thanks.

Alisha Alaimo

executive
#29

Thanks. I'll take that one. Let me begin with XUS. Following our successful U.S. launch, we keep opening up additional territories for Skyclarys, which, as mentioned before, is now offered in 34 countries, and we're happy to observe consistent, ongoing expansion once reimbursement gets approved in other markets, and that process happens market by market, with new patients being added every week, which we receive updates on. Turning to the U.S., circumstances there differ since we launched sooner, and as a result, we've achieved very strong penetration across our centers of excellence, and we estimate that 90% of the opportunity left to capture lies within the community, so patient numbers are rising, and volumes are rising too. Regarding patients stopping treatment, when we initially launched, we observed that early on, our discontinuation rates, while consistent with MOXIe, were occurring rather soon. We implemented numerous strategies throughout the past year to tackle this, involving both the field force and the medical team. And I'd say, jumping to the present, our discontinuation rates have in fact gone down; so we've enhanced our discontinuation situation through educating physicians regarding certain side effects they might observe and what patients should anticipate. The next piece, which I believe will likely affect the whole world with this launch, concerns how patients respond after being on the therapy for 12 or 18 months, because since it delays progression, it becomes quite difficult to discern what delaying progression actually looks like; we've encountered a few cases where patients stopped treatment. Following roughly a 1-year period, they deteriorated rather rapidly, and they've since returned to the product. We recognize that at that juncture, we'll implement additional strategies focused on informing the patients themselves and getting them engaged.

Tim Power

executive
#30

Let's go to the next question, please.

Andrew Tsai

analyst
#31

Hello there, and good morning. I appreciate you giving me the chance to ask something. Turning our attention back to Alzheimer's, a phase II tau dataset from your team is scheduled to arrive around the middle of 2026. What I'd like to know is what results on CDR-SB, along with how much tau reduction, you'd be hoping to observe. Also, assuming that trial turns out favorable, how would you characterize the base case and the upside case for the regulatory path? Thanks very much.

Priya Singhal

executive
#32

Okay, so on the whole, our view is that tau represents a truly significant pathological target, and the buildup of tau matters and sits at the center of Alzheimer's disease. With BIIB080, what we've done is essentially try to determine whether lowering tau — all 6 isoforms — can produce target engagement. So we'd want to observe an effect on biomarkers, both fluid and imaging, and then observe at minimum a trend toward clinical benefit. That matters for us as we consider the hypothesis. We recognize that early-stage research in AD carries a great deal of uncertainty at all times. Still, if this hypothesis holds up, the opportunity is enormous. Then, I believe your other question was about how we'd view this from a portfolio standpoint. Once we reach that point, I think we'd take a stepwise approach and ask, if it's positive, is there value in combination, parallel, or sequential dosing? Those are things we're pondering quite deeply as we consider what the best approach and result would be for patients with early Alzheimer's.

Tim Power

executive
#33

Thanks, Priya. Let's go to the next question, please.

Terence Flynn

analyst
#34

Hello, and thank you for taking my question. Perhaps I'll ask something that builds on what was just discussed, about tau. As I understand it, J&J has an anti-tau antibody moving through phase II, and some results might arrive early next year. Your company clearly has looked into this avenue too. My sense is there may be certain distinctions when it comes to binding. Still, once that J&J data appears, if we assume it lands ahead of BIIB080, what conclusions should we draw for your ASO program? Thanks, Priya.

Priya Singhal

executive
#35

Yes. From everything I gather about the J&J effort, the drug in question is posdinemab. It's a monoclonal antibody aimed at tau, and the mid-domain of tau is what it goes after. That makes it distinct. In our own history, and in the broader field's history, we've seen what happens when monoclonal antibodies are directed at tau. Up to this point, results have not been encouraging, and our view is that the key factor is the extracellular tau being targeted. In fact, that's precisely the idea Posiphen is putting to the test, so we'll have to wait and find out. They're in phase II. From what the phase I findings showed, I believe there was an effect on certain fluid biomarkers. Even so, no tau PET information emerged, and in our view that kind of data matters a great deal. So that's what we'll be watching for. As for what it tells us about our own efforts, like I mentioned, research into Alzheimer's disease using an anti-tau agent is still at an early stage. We'll need to observe the results and then make a genuine effort to interpret them. That said, should it prove effective, that would be valuable, correct, since it would settle the question of whether reducing tau truly produces an effect. So on balance I'd consider it a positive, though first we must see the data. Thank you.

Tim Power

executive
#36

Thanks, Priya. Let's go to the next one, please, Cynthia.

David Amsellem

analyst
#37

Hey, thanks. I've got a question about Zurzuvae. I just wanted to hear your perspective on how that product fits within the commercial portfolio, since it's mainly a women's health item that doesn't truly mesh with your other business units. I suppose, how are you viewing the idea of retaining the asset, now that a partner with more resources and more capital controls the remaining 50%? Thanks.

Chris Viehbacher

executive
#38

I'm not certain about the well-capitalized part, I'd say. I think we still feel that, first of all, we're extremely pleased with our partnership alongside Supernus. I mean, things are going really well there. And they've taken a different approach than Sage did. But I do think this remains a product where Biogen truly can have a meaningful role. There's an enormous unmet need. You have to shape a market. And that's an area where, commercially, Biogen is quite strong. On the resource side, I'm not so certain that even for Supernus this is a simple fit, because the prescriber base for Supernus is usually the psychiatrist. Yet in this case, the primary prescriber is actually the OB-GYN. And so the level of resourcing, I think, relative to the actual sales and profit of the product, still means this is an opportunity. I'm not sure we're eager to move into other neuropsychiatry areas, but I think when it comes to being able to create a market, Alisha and her team are doing a fantastic job. It was a difficult one because, again, this is a one-and-done treatment, and so you really need to build up prescribers who prescribe multiple times, yet the opportunity is significant. Only about 80,000 women are treated today and roughly 500,000 mothers — and this is just the U.S. alone, I believe — suffer from postpartum depression, so I think this fits very much with the ethos of Biogen, and I don't know, Alisha, whether you'd like to add anything there.

Alisha Alaimo

executive
#39

Right, so building on Chris’s point. To begin with, the Supernus partnership has kicked off extremely well. Whenever a transition takes place, they’ve handled it impressively to keep disruption to the business as small as possible. So we’re genuinely starting off on very strong footing with them; at first glance, it may seem there’s no synergy across the remaining portfolio, yet that impression only holds if you’re focused purely on the field force. When you dig deeper and examine our Biogen infrastructure — where we’re in a highly advantageous position — and consider areas such as our bio group, meaning our commercial operations team, there’s substantial synergy around data and analytics and generating insights; and in particular, our omnichannel capabilities are very robust. What’s been excellent about even bringing Zurzuvae into our portfolio is that we’ve been able to leverage considerable back-office resources to back this launch; and we think that’s partly why the launch has gone well — because of all the expertise we’ve gained from our other products and from our AI generation too. We’re also doing some quite compelling work for the Zurzuvae launch; so keep watching for additional direct-to-consumer efforts we have planned for next year, which I believe will serve as a major accelerator for Zurzuvae.

Priya Singhal

executive
#40

Perhaps I could also mention that we've secured approvals in both the E.U. and the U.K. And for mothers dealing with PPD, this marks a really significant moment, since it wasn't truly acknowledged as an entity. And that really highlights how strong the data is, along with the work put in and the high unmet need.

Tim Power

executive
#41

That's great. Let's go to our last question, please, Cynthia.

Geoff Meacham

analyst
#42

Hey everyone, this is Ross Harvey here, Geoff. So I suppose what we're asking is this: in what way is the organization approaching the deployment of capital, particularly when it comes to weighing business development against fresh product launches — above all if there appears to be a stronger emphasis on building out a pipeline at an earlier stage?

Chris Viehbacher

executive
#43

Yes. Thank you, Geoff. So to begin with, everything we're engaged in, like I mentioned before, aims at putting money into growth that can be sustained over the long haul. Through Priya's discernment, I believe we've managed to accomplish something impressive by assembling a really robust pipeline for late-stage development. You know, plenty of businesses, once they start pushing many programs into phase III trials, find themselves needing to raise their spending on R&D. Even so, we're truly spending a smaller amount than was the case 3 years back. Thus, I believe we've shown efficiency with our capital in that regard. We're also giving careful consideration to the indications themselves. Consequently, we aren't pursuing indications where we'd need to compete against, generally speaking, an AbbVie or a Sanofi or similar organizations; hence the real commercial outlay ends up being fairly limited when set against the potential. And once more, that's an area in which Biogen performs strongly. We're hiring staff to add fresh expertise in nephrology, transplant, and lupus. Yet that amounts to a comparatively modest headcount. In my view, one of the finest moments for acquiring assets is before an IND. That can be done in a way that's cost-efficient. You're able to capitalize on the reality that numerous firms possess venture capital-backed funding structured to shoulder that risk; plus you can more readily assemble a collection of early-stage assets, whether through collaboration or licensing. After that, you usher them in at the proper moment when Biogen can genuinely begin applying its more commercially focused abilities and development capabilities to mold those products. So from the standpoint of allocating capital, I believe we're capable of handling all of this; plus I think we still possess capacity; and we aren't giving up on examining later-stage assets either. However, the further along the stage, clearly, the pricier it gets; and you must be incredibly rigorous about making certain that anything you purchase will deliver a return on investment. So I believe we're in a solid position right now; and I think we hold the capital required to run the business. Naturally, though, we keep watching that closely and ensuring everything we undertake is generating shareholder value. Thank you, Chris. That wraps things up for today. I realize it's an extremely hectic morning for all of you. If you have additional questions, the IR team is available to provide answers. Thank you.

Operator

operator
#44

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.